179 related articles for article (PubMed ID: 21118937)
1. Cutaneous leishmaniasis (Leishmania major infection) in Dutch troops deployed in northern Afghanistan: epidemiology, clinical aspects, and treatment.
van Thiel PP; Leenstra T; de Vries HJ; van der Sluis A; van Gool T; Krull AC; van Vugt M; de Vries PJ; Zeegelaar JE; Bart A; van der Meide WF; Schallig HD; Faber WR; Kager PA
Am J Trop Med Hyg; 2010 Dec; 83(6):1295-300. PubMed ID: 21118937
[TBL] [Abstract][Full Text] [Related]
2. Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan.
van Thiel PP; Leenstra T; Kager PA; de Vries HJ; van Vugt M; van der Meide WF; Bart A; Zeegelaar JE; van der Sluis A; Schallig HD; van Gool T; Faber WR; de Vries PJ
Clin Infect Dis; 2010 Jan; 50(1):80-3. PubMed ID: 19951107
[TBL] [Abstract][Full Text] [Related]
3. Two cases of cutaneous leishmaniasis in Dutch military personnel treated with oral miltefosine.
van der Snoek EM; Couwenberg SM; Stijnis C; Kortbeek LM; Schadd EM
J R Army Med Corps; 2017 Feb; 163(1):68-70. PubMed ID: 26661280
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.
Dorlo TP; van Thiel PP; Huitema AD; Keizer RJ; de Vries HJ; Beijnen JH; de Vries PJ
Antimicrob Agents Chemother; 2008 Aug; 52(8):2855-60. PubMed ID: 18519729
[TBL] [Abstract][Full Text] [Related]
5. [Cutaneous leishmaniasis. Diagnosis and therapy in northern Afghanistan].
Dieterle R; Pillekamp H
Hautarzt; 2014 Feb; 65(2):125-9. PubMed ID: 24337239
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine.
Dorlo TP; van Thiel PP; Schoone GJ; Stienstra Y; van Vugt M; Beijnen JH; de Vries PJ
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1436. PubMed ID: 22180803
[TBL] [Abstract][Full Text] [Related]
7. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
Soto J; Toledo J; Gutierrez P; Nicholls RS; Padilla J; Engel J; Fischer C; Voss A; Berman J
Clin Infect Dis; 2001 Oct; 33(7):E57-61. PubMed ID: 11528586
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Miltefosine Failure and Spontaneous Resolution of Cutaneous Leishmaniasis braziliensis.
Joseph S; Whitman TJ; Buckner FS; Cogen AL
Am J Trop Med Hyg; 2021 May; 105(1):142-143. PubMed ID: 33970891
[TBL] [Abstract][Full Text] [Related]
9. Case Reports: Late Emergence of Cutaneous Leishmaniasis in an Immunocompromised Patient in a Non-Endemic Setting.
New D; Rogers BA
Am J Trop Med Hyg; 2019 Jan; 100(1):115-116. PubMed ID: 30520412
[TBL] [Abstract][Full Text] [Related]
10. In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis: Follow-Up.
Coelho AC; Trinconi CT; Costa CH; Uliana SR
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004720. PubMed ID: 27416021
[No Abstract] [Full Text] [Related]
11. Cutaneous leishmaniasis in three Dutch military cohorts following jungle training in Belize.
van Thiel PP; Zeegelaar JE; van Gool T; Faber WR; Kager PA
Travel Med Infect Dis; 2011 May; 9(3):153-60. PubMed ID: 21450527
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of miltefosine in cutaneous leishmaniasis caused by Leishmania tropica in Pakistan after antimonial treatment failure or contraindications to first line therapy-A retrospective analysis.
Kämink S; Masih B; Ali N; Ullah A; Khan SJ; Ashraf S; Pylypenko T; Grobusch MP; Fernhout J; den Boer M; Ritmeijer K
PLoS Negl Trop Dis; 2021 Jan; 15(1):e0008988. PubMed ID: 33507944
[TBL] [Abstract][Full Text] [Related]
13. Miltefosine for new world cutaneous leishmaniasis.
Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
[TBL] [Abstract][Full Text] [Related]
14. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
Vélez I; López L; Sánchez X; Mestra L; Rojas C; Rodríguez E
Am J Trop Med Hyg; 2010 Aug; 83(2):351-6. PubMed ID: 20682881
[TBL] [Abstract][Full Text] [Related]
16. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
Calvopina M; Gomez EA; Sindermann H; Cooper PJ; Hashiguchi Y
Am J Trop Med Hyg; 2006 Dec; 75(6):1074-7. PubMed ID: 17172368
[TBL] [Abstract][Full Text] [Related]
17. Miltefosine to treat cutaneous leishmaniasis caused by Leishmania tropica.
Killingley B; Lamb LE; Davidson RN
Ann Trop Med Parasitol; 2009 Mar; 103(2):171-5. PubMed ID: 19208301
[No Abstract] [Full Text] [Related]
18. Cutaneous leishmaniasis treatment.
Minodier P; Parola P
Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
[TBL] [Abstract][Full Text] [Related]
19. Miltefosine Combined with Intralesional Pentamidine for
Soto J; Soto P; Ajata A; Rivero D; Luque C; Tintaya C; Berman J
Am J Trop Med Hyg; 2018 Nov; 99(5):1153-1155. PubMed ID: 30255833
[TBL] [Abstract][Full Text] [Related]
20. [Refractory cutaneous leishmaniasis: Benefit of miltefosine].
Guerveno C; Delavigne K; Berry A; Martin-Blondel G; Delobel P
Med Mal Infect; 2019 Jun; 49(4):281-283. PubMed ID: 30554949
[No Abstract] [Full Text] [Related]
[Next] [New Search]
